
Explore how EGFR and KRAS G12C biomarkers reshape lung cancer care, from first-line choices to resistance, testing, and prognosis.

Explore how EGFR and KRAS G12C biomarkers reshape lung cancer care, from first-line choices to resistance, testing, and prognosis.

One possible way to reduce overall cost, improve patient experience, and improve outcomes in cancer care is to shift the focus of healthcare delivery away from volume and toward value. Patient-centered cancer care holds the promise of addressing these issues.